Canaccord Genuity Maintains Buy on Corcept Therapeutics, Maintains $38 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Corcept Therapeutics (NASDAQ:CORT) with a $38 price target.
July 30, 2024 | 3:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Edward Nash maintains a Buy rating on Corcept Therapeutics with a $38 price target, indicating confidence in the company's future performance.
The reaffirmation of a Buy rating and a $38 price target by a reputable analyst suggests a positive outlook for Corcept Therapeutics. This could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100